A diabetes drug in short supply for almost a year has led to what one doctor has described as "The Hunger Games" for patients trying to fill their prescriptions.
Semaglutide, a weekly injection sold under the name Ozempic, was approved by the Therapeutic Goods Administration (TGA) for lowering blood sugar in adults with type 2 diabetes, but can be prescribed off-label to treat other conditions.
